DDW Editor Reece Armstrong speaks to David Chau, Global Bioprocess Application Specialist, Purification and Filtration Business, Solventum, formerly 3M Health Care, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes.   RA: What are some of the current limitations for producing mAbs? DC: For the past few decades, there have […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!